4011 beta-barrel domain in acetyl-CoA synthetase-like proteins
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Nucleosides, nucleotides, and analogues | 85 | 24.3 | 3.50× | q < 0.0001 | |
| Homogeneous non-metal compounds | 11 | 18.9 | 0.58× | q = 0.06 | |
| Homogeneous metal compounds | 18 | 43.1 | 0.42× | q < 0.0001 | |
| Benzenoids | 1 | 6.4 | 0.16× | q = 0.04 | |
| Organoheterocyclic compounds | 2 | 13.5 | 0.15× | q = 4.4e-4 | |
| Organic oxygen compounds | 2 | 17.5 | 0.11× | q < 0.0001 | |
| Organic acids and derivatives | 1 | 13.6 | 0.07× | q < 0.0001 | |
| Lipids and lipid-like molecules | 0 | 9.8 | 0 | q = 1.7e-4 | |
| Organosulfur compounds | 1 | 1.8 | 0.55× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00131 | AMP | Adenosine phosphate | 119 |
| DB00171 | ATP | ATP | 30 |
| DB03230 | PRX | Adenosine-5'-Propylphosphate | 23 |
| DB02596 | APC | alpha,beta-Methyleneadenosine 5'-triphosphate | 13 |
| DB16833 | ADP | Adenosine disphosphate | 9 |
| DB09459 | TLA | L-tartaric acid | 5 |
| DB01992 | COA | Coenzyme A | 2 |
| DB02527 | CMP | Cyclic adenosine monophosphate | 2 |
| DB03909 | ACP | Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate | 2 |
| DB02175 | MLA | Malonic acid | 1 |
| DB03345 | BME | Mercaptoethanol | 1 |
| DB03376 | A5A | 5'-O-(N-(Alanyl)sulfamoyl)adenosine | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| AMP | ADENOSINE MONOPHOSPHATE | 159 |
| ATP | ADENOSINE-5'-TRIPHOSPHATE | 40 |
| PRX | ADENOSINE-5'-MONOPHOSPHATE-PROPYL ESTER | 31 |
| MGmetal | MAGNESIUM ION | 29 |
| ZNmetal | ZINC ION | 29 |
| 6R9 | [[(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl] ethanoate | 22 |
| CL | CHLORIDE ION | 22 |
| CAmetal | CALCIUM ION | 20 |
| ANP | PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER | 18 |
| APC | DIPHOSPHOMETHYLPHOSPHONIC ACID ADENOSYL ESTER | 14 |
| SLU | 5'-O-[N-(DEHYDROLUCIFERYL)-SULFAMOYL] ADENOSINE | 14 |
| 5SV | [(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methyl icosyl hydrogen phosphate | 10 |
| SVS | 5'-deoxy-5'-({[2-(2-hydroxyphenyl)ethyl]sulfonyl}amino)adenosine | 10 |
| WTA | 5'-O-[(S)-ethoxy(hydroxy)phosphoryl]adenosine | 10 |
| 3UK | 5'-O-[(S)-[(2-aminobenzoyl)oxy](hydroxy)phosphoryl]adenosine | 9 |
| ADP | ADENOSINE-5'-DIPHOSPHATE | 9 |
| NAmetal | SODIUM ION | 9 |
| YHF | 5'-O-[(S)-(cyclopentyloxy)(hydroxy)phosphoryl]adenosine | 9 |
| YHQ | 5'-O-{(R)-hydroxy[(propan-2-yl)oxy]phosphoryl}adenosine | 9 |
| YHT | 5'-O-{(S)-hydroxy[(prop-2-yn-1-yl)oxy]phosphoryl}adenosine | 9 |